Occupational Therapists in Palatka, FL Accepting Medicare
9 Occupational Therapists found. Showing 1 - 9
 Brooke Beasley, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 1209 Westover Dr., Palatka, FL 32177 Phone: 386-325-2249 |
Leslie Polinkas, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 108 Oakdale Dr, Palatka, FL 32177 Phone: 386-312-0022 Fax: 386-312-0535 |
Abigale Rose Such, OTR Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 1209 Westover Dr Unit 3, Palatka, FL 32177 Phone: 386-325-2249 |
Rosemarie Baskett, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3800 Saint Johns Ave, Palatka, FL 32177 Phone: 386-325-8305 |
Kaitlyn Lahart Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6061 Saint Johns Ave Ste 1, Palatka, FL 32177 Phone: 386-312-0022 |
Ms. Miranda Kyriake Rees, MOTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 322 S 18th St, Palatka, FL 32177 Phone: 386-937-2302 |
Robin Calhoun, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 611 Zeagler Dr., Palatka, FL 32177 Phone: 386-326-8500 |
Kaitlyn Mae Cremer Smith, OTD, OTR/L Occupational Therapist - Low Vision Medicare: Medicare Enrolled Practice Location: 151 W Ranch Trl, Palatka, FL 32177 Phone: 386-937-9540 |
 The Arc Of Putnam County,inc Occupational Therapist Medicare: Medicare Enrolled Practice Location: 1209 Westover Dr, Palatka, FL 32177 Phone: 386-325-2249 Fax: 386-325-3527 |
News Archive
Research unravels consequences of Zika virus attack on neural cells
Previous studies regarding the damage of the Zika virus on the brain had already pointed out the virus's predilection for a certain neural cell: the astrocyte. However, few studies have proposed to identify the infection effects on these cells, as well as their association with developmental alterations, including brain malformations and microcephaly.
Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)
Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.
Pentagon officials urge lawmakers to find savings in Medicare
As the yet-to-be named members of the debt deal's 'super committee' set to work, Pentagon officials say deep cuts in defense spending will place the nation's security at risk. Meanwhile, one of the defense budget's fastest growing line items is health care costs.
Research shows how genetic mutation causes epilepsy in infants
New research from the Howard Florey Institute in Melbourne has shown why mutation in a single gene can cause epilepsy in infants.
› Verified 1 days ago
Physical Therapists
Occupational Therapists
Speech-Language Pathologists
Chiropractors
Optometrists
Podiatrists
Audiologists